Pacer Advisors Inc. Makes New $61.66 Million Investment in Illumina, Inc. $ILMN

Pacer Advisors Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 649,290 shares of the life sciences company’s stock, valued at approximately $61,663,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. Envestnet Portfolio Solutions Inc. increased its stake in Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Arkadios Wealth Advisors grew its stake in shares of Illumina by 1.7% in the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after purchasing an additional 157 shares during the period. IMA Advisory Services Inc. grew its stake in shares of Illumina by 6.2% in the 2nd quarter. IMA Advisory Services Inc. now owns 2,853 shares of the life sciences company’s stock valued at $272,000 after purchasing an additional 167 shares during the period. Finally, Whipplewood Advisors LLC raised its holdings in shares of Illumina by 22.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 929 shares of the life sciences company’s stock worth $89,000 after buying an additional 169 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday. Cowen reissued a “hold” rating on shares of Illumina in a report on Friday, October 31st. Barclays boosted their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. TD Cowen increased their target price on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research report on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $118.31.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Gottlieb purchased 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.60% of the stock is owned by company insiders.

Illumina Stock Performance

ILMN stock opened at $134.95 on Friday. The company has a 50 day moving average price of $122.45 and a 200 day moving average price of $106.18. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $153.06. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The stock has a market capitalization of $20.62 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 2.42 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same period last year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.